68 Ga-FAPI-04 Versus 18 F-FDG PET/CT in a Case of Xanthogranulomatous Cholecystitis

Xie Y, Yang Xie, Lin X, Xinyi Lin, Yue Chen
Clinical nuclear medicine · 2025 · vol. 50(12) , pp. 1192–1193 · doi:10.1097/rlu.0000000000005984 · PMID:40829135
Case report OA: closed
View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-01 ⓘ

A case of xanthogranulomatous cholecystitis demonstrated elevated 18F-FDG and 68Ga-FAPI uptake, mimicking malignancy and suggesting the condition as a differential diagnosis for cancer-like gallbladder lesions with increased fibroblast activating protein inhibitor activity.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Xanthogranulomatous cholecystitis (XGC) is an uncommon inflammatory disease of the gallbladder. We report a case of XGC with elevated activity of 18 F-FDG and 68 Ga-FAPI (fibroblast activating protein inhibitor), which mimics malignancy. Our case suggests that XGS should be considered in the differential diagnosis of cancer-like gallbladder lesions with increased 68 Ga-FAPI uptake.

My notes (saved in your browser only)

MeSH descriptors

Cholecystitis Cholecystitis Fluorodeoxyglucose F18 Granuloma Granuloma Positron Emission Tomography Computed Tomography Xanthomatosis Xanthomatosis Gallium Radioisotopes Humans Male Middle Aged Quinolines

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
pubmed
last seen: 2026-10-08T21:51:10.529410+00:00